Akash Maniam

Dr. Akash Maniam

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Chinese Clinical Oncology
Verified
Journal Article
Open access
PDF file
RSRiya Sabharwal
Riya Sabharwal
AVArtur Vysotskyi
Artur Vysotskyi
GBGiuseppe Luigi Banna
Giuseppe Luigi Banna
AMAkash Maniam
Akash Maniam
Background and Objective: Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced urothelial carcinoma (UC) and renal cell carcinoma (RCC). Their expanding use in the adjuvant setting, aimed at eliminating micrometastatic disease post-surgery, holds significant promise. However, balancing potential survival benefits with the risk of immune-related adverse events (irAEs) in patients who are otherwise disease-free requires careful consideration. This review evaluates current evidence on adjuvant ICIs in UC and RCC, with emphasis on clinical efficacy, irAE profiles, and strategies for mitigating toxicity. Methods: A targeted literature search was performed across PubMed, Embase, Web of Science, Scopus, and the Cochrane Library, supplemented by manual review of American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) conference abstracts, to identify relevant studies on adjuvant ICI therapy in urological malignancies between 24 September 2024 and 25 January 2025. Relevant data on efficacy, safety, and irAE management were synthesized to highlight critical findings and research gaps. Key Content and Findings: Adjuvant ICIs have shown meaningful improvements in disease-free survival for patients with high-risk UC and RCC. Grade ≥3 irAEs, particularly endocrine toxicities such as hypothyroidism, adrenal insufficiency, and hypophysitis, are relatively frequent and often irreversible, necessitating lifelong hormone replacement and long-term follow-up. Although some trials have not demonstrated overall survival advantages, emerging evidence suggests biomarkers such as circulating tumour DNA (ctDNA) could guide more precise patient selection. Optimising irAE management is pivotal, as these events can significantly affect quality of life in a population that may remain disease-free. Conclusions: Adjuvant immunotherapy represents a potentially significant advance in UC and RCC, offering improved outcomes for select patients. Yet, the persistent nature of irAEs calls for vigilant surveillance, robust biomarker development, and integration of patient-reported outcomes to ensure informed clinical decision-making. The next frontier will rely on better risk stratification and toxicity mitigation to translate disease-free gains into durable, life-extending benefits. Future research that refines patient selection criteria and irAE management will be crucial for translating these survival gains into long-term benefits and shaping evidence-based guidelines in urological oncology.

12 September 2024 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
Aruni GhoseAruni Ghose
Aruni Ghose
SBSoirindhri Banerjee
Soirindhri Banerjee
PCPartha S. Choudhury
Partha S. Choudhury
AMAkash Maniam
Akash Maniam
MGManoj Gupta
Manoj Gupta
SMSwarupa Mitra
Swarupa Mitra

5 March 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
SOSarafina Urenna Otis
Sarafina Urenna Otis
GBGiuseppe Luigi Banna
Giuseppe Luigi Banna
AMAkash Maniam
Akash Maniam

23 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WZWut Yee The Zar
Wut Yee The Zar
MKMi Rim Kim
Mi Rim Kim
Aruni GhoseAruni Ghose
Aruni Ghose
SASola Adeleke
Sola Adeleke
MGManoj Gupta
Manoj Gupta
AMAkash Maniam
Akash Maniam
PET scans have long been used in oncology imaging to provide molecular and metabolic information about diseases. The use of artificial intelligence (AI) in PET scans in oncology theranostics has the potential to optimise PET modality and overcome the constraints that PET scans have, such as semi-quantitative metrics, reader subjectivity, and variability across scanners/institutions. Advances in AI and radiomics are overcoming those limitations by deep learning lesion detection, enhancing image reconstruction, and improving noise resolution, which allows ultra-low dose acquisitions, while physics-informed models integrate with PET systems to strengthen interpretability and quantitative accuracy. There are also predictive AI frameworks that link PET imaging biomarkers to therapy response and outcomes, create individualised care and are even able to simulate treatment response and help with treatment planning. However, challenges do exist. Most AI PET studies are retrospective, single-centre, and underpowered (small sample), with limited external validation and inconsistent standardisation (in acquisition, segmentation, and extraction), leading to poor reproducibility and higher performance estimates. Furthermore, ethical considerations, including data protection and transparency, need to be considered before implementation. Federated learning, physics-informed frameworks, and adherence to standardised protocols offer steps towards regulated AI systems. In summary, PET is evolving from an imaging modality to a platform with the integration of deep learning, radiomics and reconstruction capable of predicting treatment response and guiding treatment. With rigorous prospective validation, cross-institutional collaboration, and regulatory standardisation, AI in PET would create an advancement in nuclear medicine imaging in oncology.

1 June 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
KBKimberly Badal
Kimberly Badal
NMNalisha Monroe
Nalisha Monroe
AMAlisha Mohamed
Alisha Mohamed
AMAkash Maniam
Akash Maniam
MBMichelle Badal
Michelle Badal
KMKamira Maharaj
Kamira Maharaj
PURPOSE: Cancer patient navigation (CPN) training programs in the United States do not address the unique challenges of limited-resource settings. This study evaluates knowledge acquisition, utilization, and participant feedback from the Caribbean Cancer Research Institute's (CCRI) CPN training program, which trained participants from the Caribbean, Botswana, and Kenya between 2018 and 2023. METHODS: The CCRI conducted in-person CPN training in 2018 and 2019, paused in 2020 because of the COVID-19 pandemic, and transitioned to a virtual format in 2021. The program, delivered annually, expanded its curriculum and included participants from Kenya and Botswana. Knowledge acquisition was assessed through a 60-question pretest and post-test, and a 23-question program evaluation survey measured participant satisfaction. A follow-up eight-question survey assessed knowledge utilization. Summary statistics were used to describe participant demographics and survey responses, whereas paired t-tests were used to compare pretest and post-test scores. RESULTS: The virtual, self-paced CCRI CPN Training Program covered 11 topics over 12 hours. Between 2018 and 2023, 55 participants enrolled: 80% (n = 44) passed, 18% (n = 10) failed, and 2% (n = 1) did not complete the course. Most participants (95%, n = 52) were from the Caribbean, with 80% (n = 44) from Trinidad and Tobago. Three participants were from Botswana and Kenya. The majority were female (98%, n = 54) and nurses (36%, n = 20), and did not have a personal history of cancer (89%, n = 49). Significant knowledge gains ( P < .001) were observed across all years except 2023. Participants expressed high satisfaction and suggested improvements. Twenty-two percent (n = 6 of 27) secured employment as patient navigators in oncology settings. CONCLUSION: The CCRI CPN training program trained participants across the Caribbean and showed preliminary acceptability in Kenya and Botswana. Strengths include its low-cost, virtual, self-paced format, adaptability to limited-resource settings, and region-specific content. Future efforts will focus on updating training materials and expanding recruitment.

27 June 2024 in ecancermedicalscience
Verified
Journal Article
Open access
MHMona Ali Hassan
Mona Ali Hassan
AMAkash Maniam
Akash Maniam
Refugees have cancer too Mona Ali Hassan and Akash Maniam Portsmouth Hospital University NHS Trust, Portsmouth PO63LY, UK Abstract Managing